Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

被引：0

作者：

Abou-Alfa, G. K. ^{[1
]}

Borbath, I. ^{[2
]}

Clarke, S. J. ^{[3
]}

Hitre, E. ^{[4
]}

Louvet, C. ^{[5
]}

Macarulla, T. ^{[6
]}

Oh, D-Y. ^{[7
]}

Spratlin, J. L. ^{[8
]}

Valle, J. W. ^{[9
]}

Weiss, K. H. ^{[10
]}

Berman, C. ^{[11
]}

Howland, M. ^{[12
]}

Ye, Y. ^{[13
]}

Cho, T. ^{[14
]}

Moran, S. ^{[11
]}

Javle, M. M. ^{[15
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[2] Clin Univ St Luc Bruxelles, HepatoGastroenterol & Digest Oncol, Brussels, Belgium

[3] Univ Sydney, Med Oncol, Sydney, NSW, Australia

[4] Natl Inst Oncol, Med Oncol, Budapest, Hungary

[5] Inst Mutualiste Montsouris, Med Oncol, Paris, France

[6] Hosp Valle De Hebron, Med Oncol, Barcelona, Spain

[7] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea

[8] Alberta Hlth Serv, Med Oncol, Edmonton, AB, Canada

[9] Univ Manchester, Med Oncol, Christie, Manchester, Lancs, England

[10] Univ Hosp Heidelberg, Transplant Hepatol, Heidelberg, Germany

[11] QED Therapeut Inc, Clin Dev, San Francisco, CA USA

[12] QED Therapeut Inc, Clin Sci, San Francisco, CA USA

[13] QED Therapeut Inc, Biostat, San Francisco, CA USA

[14] QED Therapeut Inc, Clin Operat, San Francisco, CA USA

[15] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

832TiP

引用

页数：2

共 50 条

[31] Phase III, Open Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
Koehler, Christhardt
Marnitz, Simone
STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (10) : 666 - 668
[32] Tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma: A phase III trial in progress
Bi, Feng
Li, Han-Zhong
Zhu, Shaoxing
Zou, Qing
Tang, Jia
Zhang, Wei
Ye, Dingwei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[33] Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve
Gross-Goupil, Marine
Domblides, Charlotte
Lefort, Felix
Ravaud, Alain
BULLETIN DU CANCER, 2020, 107 (05) : ES1 - ES7
[34] Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicenter, open-label, randomized phase III controlled trial, the MIRO trial
Mariette, Christophe
Meunier, Bernard
Pezet, Denis
Dalban, Cecile
Collet, Denis
Thomas, Pascal-Alexandre
Brigand, Cecile
Perniceni, Thierry
Carrere, Nicolas
Bonnetain, Franck
Piessen, Guillaume
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[35] Neoadjuvant durvalumab plus gemcitabine and cisplatin (D plus GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)
Yoo, C.
Park, J. O.
Kim, K-P.
Hyung, J.
Ryoo, B-Y.
Hong, J. Y.
Shin, S. H.
Song, T. J.
Oh, D.
Lee, W.
Kwak, B. J.
Lee, J. H.
Hwang, D. W.
ANNALS OF ONCOLOGY, 2023, 34 : S216 - S216
[36] First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Marth, Christian
Moore, Richard G.
Bidzinski, Mariusz
Pignata, Sandro
Ayhan, Ali
Rubio, M. Jesus
Beiner, Mario
Hall, Marcia
Vulsteke, Christof
Braicu, Elena Ioana
Sonoda, Kenzo
Wu, Xiaohua
Frentzas, Sophia
Mattar, Andre
Lheureux, Stephanie
Chen, Xiaojun
Hasegawa, Kosei
Magallanes-Maciel, Manuel
Choi, Chel Hun
Shalkova, Mariia
Kaen, Diego
Wang, Peng-Hui
Berger, Regina
Okpara, Chinyere E.
Mckenzie, Jodi
Yao, Lili
Orlowski, Robert
Khemka, Vivek
Gilbert, Lucy
Makker, Vicky
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
[37] A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
Van Cutsem, E.
Bang, Y. -J.
Mansoor, W.
Petty, R. D.
Chao, Y.
Cunningham, D.
Ferry, D. R.
Smith, N. R.
Frewer, P.
Ratnayake, J.
Stockman, P. K.
Kilgour, E.
Landers, D.
ANNALS OF ONCOLOGY, 2017, 28 (06) : 1316 - 1324
[38] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
Robert, Nicholas J.
Saleh, Mansoor N.
Paul, Devchand
Generali, Daniele
Gressot, Laurent
Copur, Mehmet S.
Brufsky, Adam M.
Minton, Susan E.
Giguere, Jeffrey K.
Smith, John W., II
Richards, Paul D.
Gernhardt, Diana
Huang, Xin
Liau, Katherine F.
Kern, Kenneth A.
Davis, John
CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
[39] Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
Kitagawa, Ryo
Katsumata, Noriyuki
Shibata, Taro
Kamura, Toshiharu
Kasamatsu, Takahiro
Nakanishi, Toru
Nishimura, Sadako
Ushijima, Kimio
Takano, Masashi
Satoh, Toyomi
Yoshikawa, Hiroyuki
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2129 - U151
[40] A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.
Dalgleish, Angus George
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)

← 1 2 3 4 5 →